Mechanisms of drug resistance to immune checkpoint inhibitors in non-small cell lung cancer

Immune checkpoint inhibitors (ICIs) in the form of anti-CTLA-4 and anti-PD-1/PD-L1 have become the frontier of cancer treatment and successfully prolonged the survival of patients with advanced non-small cell lung cancer (NSCLC). But the efficacy varies among different patient population, and many p...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhou, Kexun, Li, Shuo, Zhao, Yi, Cheng, Ke
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9944349/
https://www.ncbi.nlm.nih.gov/pubmed/36845142
http://dx.doi.org/10.3389/fimmu.2023.1127071

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9944349/
https://www.ncbi.nlm.nih.gov/pubmed/36845142
http://dx.doi.org/10.3389/fimmu.2023.1127071

Ejemplares similares